Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 8, 2010, Pages 1213-1219

  Situ, Dongrong ^a   Long, Hao ^a   Lin, Peng ^a   Zhu, Zhihua ^a   Wang, Jiang ^b   Zhang, Xu ^a   Xie, Zeming ^a   Rong, Tiehua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; CD44v6; Lung cancer; Prognosis; Receiver operating characteristic curve

Indexed keywords

CD44V6 ANTIGEN; HERMES ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; ADOLESCENT; ANALYSIS OF VARIANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD44; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SURVIVAL RATE; YOUNG ADULT;

EID: 77954602453     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0771-5     Document Type: Article

References (30)

1. ASCO (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, by the American Society of Clinical Oncology. J Clin Oncol 15(8):2996-3018
2. Bains MS (1991) Surgical treatment of lung cancer. Chest 100(3):826-837
3. Carter WG, Wayner EA (1988) Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 263(9):4193-4201
4. Coradini D, Zorzet S, Rossin R et al (2004) Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 10(14):4822-4830
5. Dong WG, Sun XM, Yu BP, Luo HS, Yu JP (2003) Role of VEGF and CD44v6 in diVerentiating benign from malignant ascites. World J Gastroenterol 9(11):2596-2600
6. Fasano M, Sabatini MT, Wieczorek R, Sidhu G, Goswami S, Jagirdar J (1997) CD44 and its v6 spliced variant in lung tumors: a role in histogenesis. Cancer 80(1):34-41
7. Gunthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13-24
8. Hanley JA (1989) Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 29(3):307-335
9. Harn HJ, Ho LI, Shyu RY et al (1996) Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 22(2):107-110
10. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H (1998) Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 58(6):1108-1110
11. Kaufmann M, Heider KH, Sinn HP, von MG, Ponta H, Herrlich P (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345(8950):615-619
12. Kuhn S, Koch M, Nubel T et al (2007) A complex of EpCAM, claudin- 7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 5(6):553-567
13. Manten-Horst E, Danen EH, Smit L et al (1995) Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer 64(3):182-188
14. Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35(3):211-231
15. Miwa T, Watanabe A, Yamada Y et al (1996) Progression in gastric carcinoma relative to the ratio of CD44 epithelial variant transcript to CD44 hematopoietic variant transcript. Cancer 77(1):25-29
16. Miyoshi T, Kondo K, Hino N, Uyama T, Monden Y (1997) The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res 3(8):1289-1297
17. Mulder JW, Kruyt PM, Sewnath M et al (1994) Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344(8935):1470-1472
18. Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241-319
19. Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS, JeVrey RR (2000) Expression of CD44v6 but not E-cadherin or betacatenin inXuences prognosis in primary pulmonary adenocarcinoma. J Pathol 192(4):427-432
20. Rudzki Z, Jothy S (1997) CD44 and the adhesion of neoplastic cells. Mol Pathol 50(2):57-71
21. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350(4):379-392
22. St JT, Meyer J, Idzerda R, Gallatin WM (1990) Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 60(1):45-52
23. Stamenkovic I, Amiot M, Pesando JM, Seed B (1989) A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56(6):1057-1062
24. Stauder R, Eisterer W, Thaler J, Gunthert U (1995) CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 85(10):2885-2899
25. Suzuki H, Yamashiro K (2002) Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma. Lung Cancer 38(2):137-141
26. Tran TA, Kallakury BV, Sheehan CE, Ross JS (1997) Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 28(7):809-814
27. Wielenga VJ, Heider KH, OVerhaus GJ et al (1993) Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53(20):4754-4756
28. Wimmel A, Schilli M, Kaiser U et al (1997) Preferential histiotypic expression of CD44-isoforms in human lung cancer. Lung Cancer 16(2-3):151-172
29. Zhu ZH, Sun BY, Ma Y et al (2009) Three immunomarker support vector machines-based prognostic classiWers for stage IB nonsmall- cell lung cancer. J Clin Oncol 27(7):1091-1099
30. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A (2007) Selecting immunohistochemical cut-oV scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 60(10):1112-1116